BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kesselring AM, Wit FW, Sabin CA, Lundgren JD, Gill MJ, Gatell JM, Rauch A, Montaner JS, de Wolf F, Reiss P. Risk factors for treatment-limiting toxicities in patients starting nevirapine-containing antiretroviral therapy. AIDS. 2009;23:1689-1699. [PMID: 19487907 DOI: 10.1097/qad.0b013e32832d3b54] [Cited by in Crossref: 56] [Cited by in F6Publishing: 20] [Article Influence: 4.7] [Reference Citation Analysis]
Number Citing Articles
1 Hoen B, Bonnet F, Delaugerre C, Delobel P, Goujard C, L'Hénaff M, Persiaux R, Rey D, Rouzioux C, Taburet AM, Morlat P; 2013 French HIV expert group. French 2013 guidelines for antiretroviral therapy of HIV-1 infection in adults. J Int AIDS Soc 2014;17:19034. [PMID: 24942364 DOI: 10.7448/IAS.17.1.19034] [Cited by in Crossref: 39] [Cited by in F6Publishing: 19] [Article Influence: 5.6] [Reference Citation Analysis]
2 Neuman MG, Schneider M, Nanau RM, Parry C. HIV-Antiretroviral Therapy Induced Liver, Gastrointestinal, and Pancreatic Injury. Int J Hepatol 2012;2012:760706. [PMID: 22506127 DOI: 10.1155/2012/760706] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
3 Giacomelli A, Riva A, Falvella FS, Oreni ML, Cattaneo D, Cheli S, Renisi G, Di Cristo V, Lupo A, Clementi E, Rusconi S, Galli M, Ridolfo AL. Clinical and genetic factors associated with increased risk of severe liver toxicity in a monocentric cohort of HIV positive patients receiving nevirapine-based antiretroviral therapy. BMC Infect Dis 2018;18:556. [PMID: 30419834 DOI: 10.1186/s12879-018-3462-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
4 Mhandire D, Lacerda M, Castel S, Mhandire K, Zhou D, Swart M, Shamu T, Smith P, Musingwini T, Wiesner L, Stray-Pedersen B, Dandara C. Effects of CYP2B6 and CYP1A2 Genetic Variation on Nevirapine Plasma Concentration and Pharmacodynamics as Measured by CD4 Cell Count in Zimbabwean HIV-Infected Patients. OMICS. 2015;19:553-562. [PMID: 26348712 DOI: 10.1089/omi.2015.0104] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
5 Cordie A, Gaber Y, AbdAllah M, Vergori A, Kharono B, Omran S, Afify S, Karkouri M, Chakroun M, Musa S, Moorhouse M, Esmat G. Gastrointestinal manifestations of human immunodeficiency virus and coronavirus disease 2019: Understanding the intersecting regions between the two epidemics. Arab J Gastroenterol 2021;22:75-87. [PMID: 34120849 DOI: 10.1016/j.ajg.2021.05.014] [Reference Citation Analysis]
6 Carr DF, Chaponda M, Cornejo Castro EM, Jorgensen AL, Khoo S, Van Oosterhout JJ, Dandara C, Kampira E, Ssali F, Munderi P. CYP2B6 c.983T& gt; C polymorphism is associated with nevirapine hypersensitivity in Malawian and Ugandan HIV populations. J Antimicrob Chemother. 2014;69:3329-3334. [PMID: 25147095 DOI: 10.1093/jac/dku315] [Cited by in Crossref: 27] [Cited by in F6Publishing: 16] [Article Influence: 3.9] [Reference Citation Analysis]
7 Shet A, Antony J, Arumugam K, Kumar Dodderi S, Rodrigues R, DeCosta A. Influence of adverse drug reactions on treatment success: prospective cohort analysis of HIV-infected individuals initiating first-line antiretroviral therapy in India. PLoS One 2014;9:e91028. [PMID: 24614165 DOI: 10.1371/journal.pone.0091028] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.9] [Reference Citation Analysis]
8 Onoya D, Hirasen K, van den Berg L, Miot J, Long LC, Fox MP. Adverse Drug Reactions Among Patients Initiating Second-Line Antiretroviral Therapy in South Africa. Drug Saf 2018;41:1343-53. [PMID: 30043384 DOI: 10.1007/s40264-018-0698-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
9 du Toit JD, Kotze K, van der Westhuizen HM, Gaunt TL. Nevirapine-induced Stevens-Johnson syndrome in children living with HIV in South Africa. South Afr J HIV Med 2021;22:1182. [PMID: 33824730 DOI: 10.4102/sajhivmed.v22i1.1182] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Gandhi NR, Tate JP, Rodriguez-Barradas MC, Rimland D, Goetz MB, Gibert C, Brown ST, Mattocks K, Justice AC. Validation of an algorithm to identify antiretroviral-naïve status at time of entry into a large, observational cohort of HIV-infected patients. Pharmacoepidemiol Drug Saf 2013;22:1019-25. [PMID: 23836591 DOI: 10.1002/pds.3476] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
11 Perović Mihanović M, Haque NS, Rutherford GW, Zekan Š, Begovac J. Toxicity-related antiretroviral drug treatment modifications in individuals starting therapy: a cohort analysis of time patterns, sex, and other risk factors. Med Sci Monit 2013;19:483-92. [PMID: 23787803 DOI: 10.12659/MSM.889283] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
12 Kakande B, Isaacs T, Muloiwa R, Dlamini S, Lehloenya R. Case Report: Stevens-Johnson syndrome following a single double dosing of nevirapine-containing regimen once in an HIV-infected woman on long-term antiretroviral therapy. F1000Res 2015;4:175. [PMID: 26629333 DOI: 10.12688/f1000research.6715.1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
13 Hung WY, Abreu Lanfranco O. Contemporary review of drug-induced pancreatitis: A different perspective. World J Gastrointest Pathophysiol. 2014;5:405-415. [PMID: 25400984 DOI: 10.4291/wjgp.v5.i4.405] [Cited by in CrossRef: 50] [Cited by in F6Publishing: 30] [Article Influence: 7.1] [Reference Citation Analysis]
14 Aung AK, Haas DW, Hulgan T, Phillips EJ. Pharmacogenomics of antimicrobial agents. Pharmacogenomics 2014;15:1903-30. [PMID: 25495412 DOI: 10.2217/pgs.14.147] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
15 Phe T, Thai S, Veng C, Sok S, Lynen L, van Griensven J. Risk factors of treatment-limiting anemia after substitution of zidovudine for stavudine in HIV-infected adult patients on antiretroviral treatment. PLoS One 2013;8:e60206. [PMID: 23555926 DOI: 10.1371/journal.pone.0060206] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
16 Llibre JM, Bravo I, Ornelas A, Santos JR, Puig J, Martin-Iguacel R, Paredes R, Clotet B. Effectiveness of a Treatment Switch to Nevirapine plus Tenofovir and Emtricitabine (or Lamivudine) in Adults with HIV-1 Suppressed Viremia. PLoS One 2015;10:e0128131. [PMID: 26107265 DOI: 10.1371/journal.pone.0128131] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
17 Kahlert CR, Cipriani M, Vernazza P. Novel dual HIV maintenance therapy with nevirapine plus lamivudine retain viral suppression through 144 weeks-A proof-of-concept study. PLoS One 2020;15:e0237770. [PMID: 32966293 DOI: 10.1371/journal.pone.0237770] [Reference Citation Analysis]
18 Ena J, Amador C, Benito C, Pasquau F. Pharmacological and clinical evidence of nevirapine immediate- and extended-release formulations. HIV AIDS (Auckl) 2012;4:169-79. [PMID: 23172991 DOI: 10.2147/HIV.S35564] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
19 Thorsteinsson K, Ladelund S, Jensen-Fangel S, Johansen IS, Katzenstein TL, Pedersen G, Storgaard M, Obel N, Lebech AM. Impact of gender on response to highly active antiretroviral therapy in HIV-1 infected patients: a nationwide population-based cohort study. BMC Infect Dis 2012;12:293. [PMID: 23140254 DOI: 10.1186/1471-2334-12-293] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
20 Schouten JT, Krambrink A, Ribaudo HJ, Kmack A, Webb N, Shikuma C, Kuritzkes DR, Gulick RM. Substitution of nevirapine because of efavirenz toxicity in AIDS clinical trials group A5095. Clin Infect Dis 2010;50:787-91. [PMID: 20121419 DOI: 10.1086/650539] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]